Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Tvardi Therapeutics Inca Clinical-Stage Biopharmaceutical Company Focused On The Development Of Novel, Oral, Small Molecule Therapies Targeting Signal Transducer And Activator Of Transcription 3 (Stat3) To Treat Inflammatory And Proliferative Diseases With Unmet Need. Its Pipeline Includes Two Oral, Small Molecule Stat3 Inhibitors: Tti-101 And Tti-109. Tti-101 Is Its First-Generation Direct Stat3 Inhibitor, Currently In Phase 1b/2 Clinical Development In Hepatocellular Carcinoma (Hcc). Tti-109 Is A Phosphate Prodrug Of Tti-101 That Is Mechanistically Identical To Its Parent Molecule But Is Designed To Enhance Its Ability To Target Stat3.